Using engineered immunity and synthetic immunology to investigate the underlying mechanisms of antibody-mediated treatment and prevention of infectious disease.
Our latest manuscript just came out in @ImmunityCP describing over a decade of work in the lab studying HIV evolution and escape from HIV broadly neutralizing antibodies.
https://t.co/VyY37KJQHd
Our latest manuscript just came out in @ImmunityCP describing over a decade of work in the lab studying HIV evolution and escape from HIV broadly neutralizing antibodies.
https://t.co/VyY37KJQHd
Our results suggest that decreasing viral fitness may synergize with bNAbs when treating HIV infection. However,I want to stress that all of this work was done in humanized mice and in vitro, which may not entirely recapitulate results we might see in actual humans.
“We believe this insight will be crucial for the development of future HIV therapies that employ combinations of antibodies that can exert orthogonal selective pressure on the virus."
Read More: https://t.co/Vf7Kre2w7Y
Proud to share our latest paper on SARS-CoV-2 vaccines and the variants that have emerged (and continue to emerge). Bottom line is the latest versions of the mRNA boosters are doing a pretty good job of keeping up with variants.
https://t.co/fxEyPhDnlj
Ragon faculty member Alejandro Balazs, PhD, has been awarded a prestigious Avant-Garde Award for HIV and Substance Use Disorder Research from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH).
#HIV#Research#NIDA#NIH#Award